CA3243690A1 - Protéines de liaison à l'antigène qui se lient à b7-h3 - Google Patents

Protéines de liaison à l'antigène qui se lient à b7-h3

Info

Publication number
CA3243690A1
CA3243690A1 CA3243690A CA3243690A CA3243690A1 CA 3243690 A1 CA3243690 A1 CA 3243690A1 CA 3243690 A CA3243690 A CA 3243690A CA 3243690 A CA3243690 A CA 3243690A CA 3243690 A1 CA3243690 A1 CA 3243690A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243690A
Other languages
English (en)
Inventor
Andreas Herrmann
Damien Bresson
Heyue Zhou
Weiqun SHEN
Original Assignee
Vivasor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivasor Inc filed Critical Vivasor Inc
Publication of CA3243690A1 publication Critical patent/CA3243690A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"La présente divulgation concerne des protéines de liaison à B7-H3, en particulier des anticorps anti-B7-H3, ou des parties de liaison à l’antigène associées, qui se lient spécifiquement à B7-H3 et leurs utilisations. Divers aspects des anticorps anti-B7-H3 portent sur des fragments d’anticorps, des anticorps à chaîne unique, des compositions pharmaceutiques, des acides nucléiques, des vecteurs d’expression recombinants, des cellules hôtes, et des procédés de préparation et des méthodes d’utilisation de tels anticorps anti-B7-H3. Des méthodes d’utilisation des anticorps anti-B7-H3 comprennent des méthodes in vitro et in vivo pour lier B7-H3 et traiter des maladies associées à l’expression de B7-H3."
CA3243690A 2022-02-04 2023-02-03 Protéines de liaison à l'antigène qui se lient à b7-h3 Pending CA3243690A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306938P 2022-02-04 2022-02-04
US63/306,938 2022-02-04
PCT/US2023/061996 WO2023150724A2 (fr) 2022-02-04 2023-02-03 Protéines de liaison à l'antigène qui se lient à b7-h3

Publications (1)

Publication Number Publication Date
CA3243690A1 true CA3243690A1 (fr) 2023-08-10

Family

ID=87553042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243690A Pending CA3243690A1 (fr) 2022-02-04 2023-02-03 Protéines de liaison à l'antigène qui se lient à b7-h3

Country Status (5)

Country Link
EP (1) EP4473018A2 (fr)
JP (1) JP2025507305A (fr)
CN (1) CN119053621A (fr)
CA (1) CA3243690A1 (fr)
WO (1) WO2023150724A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121969397A (zh) * 2023-04-05 2026-05-01 维硕公司 抗体偶联药物及其用途
US20250197501A1 (en) * 2023-12-19 2025-06-19 Development Center For Biotechnology Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872018A1 (fr) * 2012-05-17 2013-11-21 Sorrento Therapeutics, Inc. Proteines de liaison antigeniques se liant a egfr
CA2955086A1 (fr) * 2014-08-08 2016-02-11 Alector Llc Anticorps anti-trem2 et leurs procedes d'utilisation
US12312406B2 (en) * 2018-11-09 2025-05-27 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof

Also Published As

Publication number Publication date
CN119053621A (zh) 2024-11-29
EP4473018A2 (fr) 2024-12-11
JP2025507305A (ja) 2025-03-18
WO2023150724A3 (fr) 2023-09-14
WO2023150724A2 (fr) 2023-08-10

Similar Documents

Publication Publication Date Title
US20250084163A1 (en) Antigen Binding Proteins That Bind ROR1
JP2018513149A (ja) Ｃｄ３８に結合する抗体治療剤
JP7555953B2 (ja) Ｃｄ３８に結合する操作されたバリアント抗体
US20210388097A1 (en) Antigen Binding Proteins that Bind BCMA
WO2023150724A2 (fr) Protéines de liaison à l'antigène qui se lient à b7-h3
JP2024036508A (ja) Ｃｄ３８に結合するバリアント抗体
US20230235059A1 (en) Anti-pd1 antibodies and uses thereof
EP4613774A1 (fr) Anticorps à domaine unique ciblant ror1 humain
US20230147852A1 (en) Engineered Antibodies That Bind LAG3
HK40064182A (en) Antigen binding proteins that bind bcma

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240802

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240806

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240806

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240819

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241003

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241112

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250808

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251008

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260317